Article thumbnail

Low Anaerobic Threshold and Increased Skeletal Muscle Lactate Production in Subjects with Huntington's Disease

By Andrea Ciammola, Jenny Sassone, Monica Sciacco, Niccolò E Mencacci, Michela Ripolone, Caterina Bizzi, Clarissa Colciago, Maurizio Moggio, Gianfranco Parati, Vincenzo Silani and Gabriella Malfatto


Mitochondrial defects that affect cellular energy metabolism have long been implicated in the etiology of Huntington's disease (HD). Indeed, several studies have found defects in the mitochondrial functions of the central nervous system and peripheral tissues of HD patients. In this study, we investigated the in vivo oxidative metabolism of exercising muscle in HD patients. Ventilatory and cardiometabolic parameters and plasma lactate concentrations were monitored during incremental cardiopulmonary exercise in twenty-five HD subjects and twenty-five healthy subjects. The total exercise capacity was normal in HD subjects but notably the HD patients and presymptomatic mutation carriers had a lower anaerobic threshold than the control subjects. The low anaerobic threshold of HD patients was associated with an increase in the concentration of plasma lactate. We also analyzed in vitro muscular cell cultures and found that HD cells produce more lactate than the cells of healthy subjects. Finally, we analyzed skeletal muscle samples by electron microscopy and we observed striking mitochondrial structural abnormalities in two out of seven HD subjects. Our findings confirm mitochondrial abnormalities in HD patients' skeletal muscle and suggest that the mitochondrial dysfunction is reflected functionally in a low anaerobic threshold and an increased lactate synthesis during intense physical exercise. © 2010 Movement Disorder Societ

Topics: Research Article
Publisher: Wiley Subscription Services, Inc., A Wiley Company
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy.
  2. Abnormal morphology of peripheral cell tissues from patients with Huntington disease.
  3. Cardiopulmonary exercise testing and its application.
  4. (1988). Conditions associated with Huntington’s disease at death. A case-control study.
  5. (1999). Critical capillary PO2 and the role of lactate production in oxyhemoglobin dissociation during exercise. Adv Exp Med Biol
  6. (1993). CSF and serum metabolic profile of patients with Huntington’s chorea: a study by high resolution proton NMR spectroscopy and HPLC.
  7. DiMauro S.Mitochondrial disorders in Neurology.-Boston, MA:Butterworth and Heinemann;1994.
  8. (1997). Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10.
  9. (1993). gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes.
  10. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington’s disease.
  11. Huntington’s disease. The current state of research with peripheral tissues.
  12. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington’s disease subjects.
  13. (1978). Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies.
  14. Lack of apoptosis in mitochondrial encephalomyopathies.
  15. Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure.
  16. (1994). Mitochondrial diseases of muscle.
  17. (2005). Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord
  18. (2007). Myopathy as a first symptom of Huntington’s disease in a Marathon runner. Mov Disord
  19. PGC-1 alpha, a new therapeutic target in Huntington’s disease?Cell 2006;127:465–468.
  20. Physical therapy intervention for people with Huntington disease.
  21. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington’s disease mutation.
  22. Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: indication of glial energy impairment in Huntington chorea, but not Parkinson disease.
  23. Rate and correlates of weight change in Huntington’s disease.
  24. (2009). Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease.
  25. Studies on brain biopsies of patients with Huntington’s chorea.
  26. (1992). The benefits of the low intensity training. Ann Physiol Anthropol
  27. Transcriptional repression of PGC-1 alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.
  28. Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington’s disease.
  29. (1995). Widespread expression of Huntington’s disease gene (IT15) protein product. Neuron